Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Int J Cardiovasc Imaging ; 35(6): 1009-1017, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30941563

ABSTRACT

Right ventricular (RV) impairment after cancer therapy-related cardiotoxicity and its prognostic implications in lung cancer have not been examined. The present research sought to evaluate RV structure, function, and mechanics in stage III non-small-cell lung cancer (NSCLC) before and after concurrent chemoradiotherapy (CCRT), and to explore the associations between RV impairments, radiation dose, and all-cause mortality. This prospective investigation included 128 inoperable NSCLC patients who were scheduled to receive CCRT. Echocardiographic examination and strain evaluation was performed at baseline and 6 months post-CCRT in all participants. Conventional RV dimensions revealed no significant changes post-CCRT. However, a reduction in RV free wall strain (RV-fwLS) was observed at 6 months post-CCRT (- 28.3 ± 4.6% vs. - 25.5 ± 4.8%, P < 0.001). The same was revealed for global RV longitudinal strain (RV-GLS) (- 23.4 ± 2.9% vs. - 20.2 ± 3.4%, P < 0.001). Pearson correlation showed that RV radiation mean dose was related with the percentage change in RV-fwLS (r = 0.303, P = 0.001) and RV-GLS (r = 0.284, P = 0.002). In multivariable analysis, the percentage change in RV-fwLS was an independent predictor of all-cause mortality (HR 1.296, 95% CI 1.202-1.428, P < 0.001). RV longitudinal strain is deteriorated at 6 months post-CCRT. The RV mechanics deterioration was associated with radiation dose and affected the long-term outcome of stage III NSCLC patients treated with CCRT.


Subject(s)
Carcinoma, Non-Small-Cell Lung/therapy , Chemoradiotherapy/adverse effects , Lung Neoplasms/therapy , Myocardial Contraction/radiation effects , Radiation Injuries/etiology , Radiotherapy Dosage , Ventricular Dysfunction, Right/etiology , Ventricular Function, Right/radiation effects , Adolescent , Adult , Aged , Biomechanical Phenomena , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Cardiotoxicity , Chemoradiotherapy/mortality , Echocardiography, Doppler , Female , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Male , Middle Aged , Myocardial Contraction/drug effects , Neoplasm Staging , Prospective Studies , Radiation Injuries/diagnostic imaging , Radiation Injuries/physiopathology , Time Factors , Treatment Outcome , Ventricular Dysfunction, Right/diagnostic imaging , Ventricular Dysfunction, Right/physiopathology , Ventricular Function, Right/drug effects , Young Adult
2.
Heart Fail Clin ; 13(2): 327-336, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28279418

ABSTRACT

End-stage heart failure in cancer survivors may result from cardiotoxic chemotherapy and/or chest radiation and require advanced therapies, including left ventricular assist devices (LVADs) and transplantation. Traditionally, such therapies have been underutilized in cancer survivors owing to lack of experience and perceived risk of cancer recurrence. Recent data from large registries, however, have shown excellent outcomes of LVADs and transplantation in cancer survivors, albeit subject to careful selection and special considerations. This article summarizes all aspects of advanced heart failure therapies in patients with cancer therapy-related cardiac dysfunction and underscores the need for careful selection of these candidates.


Subject(s)
Heart Failure/therapy , Heart Ventricles/physiopathology , Neoplasms/therapy , Cardiac Resynchronization Therapy , Female , Heart Failure/etiology , Heart Transplantation , Heart-Assist Devices , Humans , Male , Middle Aged , Neoplasms/complications , Patient Selection , Registries , Ventricular Function, Left/drug effects , Ventricular Function, Left/radiation effects , Ventricular Function, Right/drug effects , Ventricular Function, Right/radiation effects
3.
Med. clín (Ed. impr.) ; 148(3): 101-106, feb. 2017. tab, graf
Article in Spanish | IBECS | ID: ibc-160050

ABSTRACT

Introducción y objetivos: Los pacientes pequeños para la edad gestacional (PEG) son población de riesgo para el desarrollo de enfermedad cardiovascular y síndrome metabólico. Nuestro objetivo es estudiar la morfología y la función cardiaca en un grupo de niños PEG en edad escolar en tratamiento con growth hormone (GH, «hormona de crecimiento»). Métodos: Se han incluido en el estudio 23 pacientes PEG y 23 controles sanos. Se valoró peso, talla, presión arterial y frecuencia cardiaca. Mediante ecocardiografía transtorácica se evaluó el tamaño de las cavidades cardiacas, el diámetro de la aorta ascendente y abdominal y parámetros de función biventricular. Resultados: Los niños PEG presentan mayores percentiles de presión arterial sistólica y diastólica (p < 0,05), sin cambios significativos en la frecuencia cardiaca. Tienen un mayor diámetro del septo interventricular (Z-score 1,57 en PEG frente a 0,89; p = 0,026) y una peor función sistólica del ventrículo derecho, con un TAPSE inferior (Z-score −0,98 en PEG frente a 0,95; p = 0,000) y una menor velocidad sanguínea en arteria pulmonar (0,85 m/s en PEG frente a 0,97 m/s; p = 0,045). No se han encontrado diferencias en la función del ventrículo izquierdo. El diámetro de la aorta ascendente es mayor en PEG (Z-score−1,09 frente a−1,93; p = 0,026), mientras que el diámetro de la aorta abdominal en sístole es menor (Z-score −0,89 frente a −0,19; p = 0,015). Conclusiones: Se han observado cambios significativos en la morfología y la función cardiaca en niños PEG en edad escolar tratados con GH. Es importante continuar en ellos un seguimiento para determinar si estas alteraciones contribuyen a un aumento de morbilidad cardiaca en la edad adulta (AU)


Introduction and objectives: Small for gestational age (SGA) patients have an increased risk of developing a cardiovascular pathology, as well as a metabolic syndrome. Our objective is to evaluate the cardiac morphology and function of SGA children treated with growth hormone (GH), identifying changes that could potentially have long-term consequences. Methods: We selected 23 SGA school-age patients and 23 healthy children. We measured their weight, height, blood pressure and heart rate. Using transthoracic echocardiography, we evaluated cardiac chamber size, ascending and abdominal aortic diameter as well as the systolic and diastolic function of both ventricles. Results: SGA children have a higher systolic and diastolic blood pressure (P < .05) without significant changes in their heart rate. They also have a thicker interventricular septum (SGA Z-score 1.57 vs. 0.89; P = .026) and a worse right ventricular systolic function, with a lower TAPSE (SGA Z-score −0.98 vs. 0.95; P = .000), as well as a lower blood flow rate in the pulmonary artery (SGA 0.85 m/s vs. 0.97 m/s; P = .045). No significant difference was observed in the patients’ left ventricular function. SGA patients’ ascending aortic diameter was greater (SGA Z-score −1.09 vs. −1.93; P = .026), whereas the systolic abdominal aortic diameter was smaller (SGA Z-score−0.89 vs. −0.19; P = .015). Conclusions: We found functional and morphological cardiac changes in SGA school-age patients treated with GH. It is important to follow-up this patient group in order to determine if these changes contribute to an increased cardiac morbidity in adulthood (AU)


Subject(s)
Humans , Male , Female , Child , Heart Function Tests/methods , Gestational Age , Growth Hormone/therapeutic use , Risk Groups , Heart Ventricles/pathology , Heart Ventricles , Aorta, Abdominal/pathology , Aorta, Abdominal , Heart Rate , Heart Rate/physiology , Ventricular Function, Right/physiology , Ventricular Function, Right/radiation effects , Echocardiography , Body Mass Index , Analysis of Variance , Body Composition/radiation effects
SELECTION OF CITATIONS
SEARCH DETAIL
...